Hans-Peter Hartung

Affiliations: 
Department of Neurology Heinrich-Heine-Universitat Dusseldorf, Germany 
Google:
"Hans-Peter Hartung"
Mean distance: 106866
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Albrecht P, Jansen A, Lee JI, et al. (2019) Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 93: 768-769
Albrecht P, Jansen A, Lee JI, et al. (2019) Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 93: 767-768
Cree BAC, Bennett JL, Kim HJ, et al. (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet (London, England)
Sinnecker T, Hadisurya J, Schneider-Hohendorf T, et al. (2019) Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. Bmc Neurology. 19: 190
Warnke C, Hartung HP. (2019) Big data in MS-What can we learn from large international observational studies such as MSBase? Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519868982
Lee JI, Gemerzki L, Boerker L, et al. (2019) No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. Frontiers in Neurology. 10: 741
Förster M, Graf J, Mares J, et al. (2019) Drug Treatment of Clinically Isolated Syndrome. Cns Drugs. 33: 659-676
Graf J, Ingwersen J, Lepka K, et al. (2019) Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. Acta Neurologica Scandinavica
Manouchehri N, Zhang Y, Salter A, et al. (2019) Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders. 12: 1756286419847095
Schweitzer F, Laurent S, Fink GR, et al. (2019) Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Current Opinion in Neurology
See more...